Comparative Pharmacology
Head-to-head clinical analysis: FUROXONE versus TRIVAGIZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROXONE versus TRIVAGIZOLE 3.
FUROXONE vs TRIVAGIZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
Terconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
100 mg orally four times daily
One vaginal tablet (200 mg) inserted intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Terminal elimination half-life is approximately 7-9 hours in healthy adults, allowing for twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged up to 18 hours, requiring dose adjustment.
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Renal excretion accounts for approximately 70-80% of the administered dose, with about 20% excreted as unchanged drug and the remainder as metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
Antibacterial/Antiprotozoal
Antibacterial/Antifungal Combination